HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Vaccine-Immunotherapy combo targets multiple cancers in early trial
Disease control OngoingThis phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 23, 2026 19:31 UTC
-
New Dual-Antibody combo tackles multiple advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with various advanced solid tumors that have spread or come back. The main goals are to find a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 23, 2026 19:31 UTC
-
Experimental cocktail aims to tackle Hard-to-Treat head and neck cancer
Disease control OngoingThis early-phase trial is testing a new combination of an experimental drug (INCB081776), an immunotherapy (pembrolizumab), and radiation therapy in 10 people with advanced head and neck cancer that has spread or come back. The main goal is to check safety and side effects, while…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 23, 2026 19:16 UTC
-
New drug duo aims to fight Hard-to-Treat head and neck cancer
Disease control OngoingThis phase II trial tests a new drug called SI-B001 combined with the chemotherapy paclitaxel in 42 adults with recurrent or metastatic head and neck squamous cell carcinoma that has worsened after prior treatments. The goal is to see if the combination is safe and can shrink tum…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
Experimental drug SI-B001 tested in stubborn head and neck cancers
Disease control OngoingThis phase II trial tests an experimental drug called SI-B001 in 11 adults with recurrent or metastatic head and neck cancer that has worsened after standard treatments. The drug is given weekly by IV infusion. The main goal is to see if tumors shrink, while also monitoring safet…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Promising cancer combo trial pulled before it even started
Disease control TerminatedThis study was designed to test whether adding an experimental drug called TTI-101 to the immunotherapy pembrolizumab (Keytruda) is safe and effective for people with head and neck cancer that has returned or spread. The trial was withdrawn before enrolling any participants, so n…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
New cancer drug ABBV-400 enters early human testing
Disease control OngoingThis early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
Donor immune cells take on Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
Immune drugs given before surgery show promise against multiple cancers
Disease control OngoingThis phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New combo therapy targets Hard-to-Treat head and neck cancers
Disease control OngoingThis study tests a new drug called NT219 combined with either pembrolizumab or cetuximab in people with head and neck cancer that has come back or spread. The goal is to see if these combinations can shrink tumors. The trial involves 29 adults whose cancer cannot be cured with st…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New cocktail aims to tame incurable head and neck cancer
Disease control OngoingThis study tests a three-drug combination called CACTUX (cisplatin, nab-paclitaxel, and cetuximab) in 74 people with head and neck cancer that cannot be cured. The goal is to see if this mix works better and causes fewer side effects than the standard treatment. Participants have…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control OngoingThis study tests an experimental pill called IPN01194 in adults with advanced solid tumors (melanoma, colorectal, pancreatic, or head and neck cancers) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 36 …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
Head and neck cancer: which chemo combo works best?
Disease control OngoingThis study compares two chemotherapy combinations for people with advanced head and neck cancer that hasn't been treated yet. One group gets paclitaxel, carboplatin, and cetuximab weekly; the other gets cetuximab, docetaxel, cisplatin, and fluorouracil in cycles. The goal is to s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
Experimental cocktail aims to revive immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
Experimental drug combo aims to boost immunotherapy in tough cancers
Disease control OngoingThis study tests an experimental drug called ARRY-614 combined with standard immunotherapy drugs (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors, including lung, head and neck, kidney, and skin cancers. The first part of the trial finds a safe dose, …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
New drug cocktail aims to shrink head and neck tumors better than standard care
Disease control OngoingThis study tests whether adding an experimental drug (domvanalimab) to a standard immunotherapy (zimberelimab) plus chemotherapy works better than the standard immunotherapy plus chemotherapy alone for people with head and neck cancer that has spread or come back. About 100 adult…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC
-
New DNA vaccine combo aims to fight advanced head and neck cancer
Disease control OngoingThis study tests a combination of a DNA vaccine (GX-188E), an immune booster (GX-I7), and an immunotherapy drug (nivolumab) in adults with HPV 16- or 18-positive head and neck cancer that has spread or returned after platinum chemotherapy. The goal is to see if this combination c…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The main goal is to find a safe dose and check for side effects. About 72 participants will take par…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
New antibody IMT-009 tested in advanced cancers – hope for Hard-to-Treat tumors
Disease control OngoingThis early-phase trial tests a new antibody drug called IMT-009 in about 67 people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose, understand side effects, and see if the drug can shrink tumors. The s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Immunitas Therapeutics • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
Could a diabetes drug help fight head and neck cancer? new study tests combo therapy
Disease control OngoingThis study tested whether combining the immunotherapy drug pembrolizumab with the diabetes drug metformin could help shrink tumors in people with advanced head and neck cancer that has spread. The trial enrolled 21 adults whose cancer could not be cured with surgery or radiation.…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New drug combo aims to boost immune attack on head and neck tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—nivolumab and an anti-IL-8 antibody—before surgery is safe and feasible for people with head and neck cancer. About 24 participants will receive the combination before their operation. The goal is to see if this approach can help shrink t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC
-
Immunotherapy may replace chemo in head and neck cancer trial
Disease control OngoingThis study tests whether the immunotherapy drug pembrolizumab (Keytruda) combined with radiation works better than the standard chemotherapy drug cisplatin with radiation for patients with a certain type of head and neck cancer (p16-positive). About 126 adults with advanced or in…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Loren Mell, MD • Aim: Disease control
Last updated Jun 16, 2026 12:55 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs (naptumomab estafenatox and durvalumab) in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and see if the combination can shrink tumors. About 120 …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: NeoTX Therapeutics Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New combo therapy before surgery shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether giving a short course of radiation plus an immunotherapy drug (pembrolizumab) before surgery can shrink advanced head and neck cancers more effectively. About 28 adults with stage III or IV HPV-negative head and neck cancer will receive this neoadjuvant t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New cocktail of cancer drugs shows promise in head and neck tumors
Disease control OngoingThis study tests whether combining three different medicines (BI 770371, pembrolizumab, and cetuximab) can shrink tumors better than pembrolizumab alone in adults with advanced head and neck cancer. Participants are randomly assigned to one of three treatment groups and receive i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New dual-action antibody enters early trials for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The study aims to find a safe dose and see if the drug can sh…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New drug combo aims to boost radiation for head and neck cancer
Disease control OngoingThis early-phase study tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation for people with advanced head and neck cancer that has spread to nearby tissues or lymph nodes. The main goal is to find the safest dose and check for side…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Immunotherapy boost before surgery shows promise against head and neck cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck cancer. About 122 participants will be randomly assigned to receive either the drug combo or chemo alone for thr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New hope for head and neck cancer: drug combo trial launches
Disease control OngoingThis study tests whether adding other drugs to tislelizumab helps shrink or control head and neck cancer that has returned or spread. About 160 adults with certain types of this cancer will receive the treatment as their first therapy for advanced disease. The goal is to see if t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New drug duo aims to shrink tough head and neck tumors
Disease control OngoingThis study tests two different doses of the experimental drug FID-007 combined with cetuximab in people with advanced head and neck cancer that has come back or spread. About 46 adults whose cancer worsened after immunotherapy will be randomly assigned to one of two dosing schedu…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New three-step combo targets tough head and neck cancers
Disease control OngoingThis study tests a three-step treatment plan for people with a type of head and neck cancer not caused by HPV. First, patients take a drug called palbociclib before standard chemoradiation, then receive chemoradiation, and finally take palbociclib again after treatment. The goal …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
Voice-Saving cancer trial: which chemo timing works best?
Disease control OngoingThis study tests two ways to treat advanced larynx or hypopharynx cancer while trying to avoid removing the voice box. One group gets chemotherapy before radiation, the other gets chemo during radiation. The goal is to see which approach better preserves larynx function two years…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New drug duo aims to boost immune attack on head and neck tumors
Disease control OngoingThis early-phase study tests whether giving two immune-boosting drugs (LVGN7409 and a PD-1 inhibitor) before surgery can safely help the body fight HPV-negative head and neck cancer. About 27 adults with resectable tumors will receive the combination, then undergo surgery. The ma…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
HPV vaccine combo shows promise against head and neck cancer in early trial
Disease control OngoingThis study tests whether combining an HPV DNA vaccine with immunotherapy drugs can shrink advanced head and neck cancers caused by HPV types 16 or 18 before surgery. About 56 adults with resectable tumors will receive one of three treatment combinations. The main goal is to see i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
New combo therapy aims to extend life without sacrificing quality in advanced head and neck cancer
Disease control OngoingThis study looks at adults with head and neck cancer that has spread to 1-3 other spots (oligometastases). It compares two treatments: stereotactic radiotherapy alone versus radiotherapy plus chemotherapy. The goal is to see which approach helps people live longer with a good qua…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
New combo therapy aims to reignite immune attack on drug-resistant tumors
Disease control OngoingThis study is for adults with advanced lung, skin, kidney, or head-and-neck cancers that have stopped responding to standard immunotherapy. The treatment combines an immune-boosting drug injected directly into a tumor, targeted radiation, and an immunotherapy drug (pembrolizumab)…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug (sEphB4-HSA) combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and check for side effects. About 61 …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 03, 2026 12:03 UTC
-
New drug combo aims to keep head and neck cancer at bay
Disease control OngoingThis study looks at whether adding lenvatinib to pembrolizumab (a type of immunotherapy) after standard chemoradiation can help prevent head and neck cancer from coming back. About 50 adults with advanced, PD-L1 positive head and neck cancer will take part. The goal is to see if …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Jun 01, 2026 17:54 UTC
-
New Light-Based scanner could spot hidden cancer in neck lymph nodes
Diagnosis TerminatedThis study is testing a new imaging device called MSOT that uses light and sound to create detailed pictures of neck lymph nodes in people with head and neck cancer. The goal is to see if it can more accurately detect cancer spread and radiation-induced scarring than current meth…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 22, 2026 11:58 UTC
-
3D tumor maps could sharpen radiation targeting in head and neck cancer
Knowledge-focused OngoingThis study tests whether creating a virtual 3D map of a patient's removed tumor helps doctors plan radiation therapy more precisely. Researchers will compare standard radiation plans with plans that include the 3D map to see if it changes the treatment area or reduces radiation t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 23, 2026 19:16 UTC
-
Cancer test study pulled before it even started
Knowledge-focused TerminatedThis study planned to check if a new test, called OncoPrism-HNSCC, could predict how well immunotherapy would work in people with head and neck cancer that had spread. Researchers would have looked at tumor samples taken before treatment to see if the test could tell who would be…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Cofactor Genomics, Inc. • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:52 UTC
-
Does more frequent Check-Ups after head and neck cancer save lives?
Knowledge-focused OngoingThis study looks at whether a more intensive follow-up schedule after treatment for head and neck cancer helps people live longer compared to a standard schedule. It involves 197 smokers or heavy drinkers over age 35 who are cancer-free 2-4 months after treatment. The goal is to …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:04 UTC